Johnson & Johnson engages in the manufacture and sale of various products in the health care field worldwide.
There is no perfect dividend growth stock, but JNJ comes close. The company enjoys a diverse revenue base, an excellent research pipeline, a pristine balance sheet and exceptional free cash-flows to cover it dividend. This diversity and strength will help the company overcome near-term results from patent losses on Risperdal and Topamax. I will continue to add to my position as my allocation allows and when JNJ is trading below my buy price of $70.24.
Source: Dividends Value
Related Articles:
Dividend Growth Stocks News
- 3 Asian Dividend Stocks To Watch With Up To 4.4% Yield - Yahoo Finance - 4/3/2025
- 3 Rock-Solid Dividend Stocks That Will Grow Passive Income This Year - 24/7 Wall St. - 4/3/2025
- Top ASX Dividend Stocks To Consider - Yahoo Finance - 4/3/2025
- Dividend Stocks To Follow Today - April 1st - MarketBeat - 4/3/2025
- Dividend Stocks: Smoking-Hot 7% Yield Lights Up Demand - Investor's Business Daily - 4/3/2025
- Cisco Systems, Inc. (CSCO) Dividend Stock Analysis - 3/28/2025
- Sysco Corporation (SYY) Dividend Stock Analysis - 3/21/2025
- Union Pacific Corporation (UNP) Dividend Stock Analysis - 3/14/2025
- Kellogg Company (K) Dividend Stock Analysis - 3/7/2025
- Texas Instruments Inc. (TXN) Dividend Stock Analysis - 2/28/2025
Stock Analysis: Johnson & Johnson (JNJ)
Posted by D4L | Thursday, May 27, 2010 | ArticleLinks | 0 comments »________________________________________________________________
Subscribe to:
Post Comments (Atom)
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.